CN115040616A - Dampness eliminating tea and application thereof - Google Patents
Dampness eliminating tea and application thereof Download PDFInfo
- Publication number
- CN115040616A CN115040616A CN202210907559.7A CN202210907559A CN115040616A CN 115040616 A CN115040616 A CN 115040616A CN 202210907559 A CN202210907559 A CN 202210907559A CN 115040616 A CN115040616 A CN 115040616A
- Authority
- CN
- China
- Prior art keywords
- parts
- dampness
- spleen
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001122767 Theaceae Species 0.000 title description 10
- 239000003814 drug Substances 0.000 claims abstract description 71
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 210000000952 spleen Anatomy 0.000 claims abstract description 39
- 244000197580 Poria cocos Species 0.000 claims abstract description 27
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 27
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 27
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 26
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 24
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 24
- 244000268590 Euryale ferox Species 0.000 claims abstract description 23
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 23
- 235000012874 Phaseolus calcaratus Nutrition 0.000 claims abstract description 23
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 22
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 22
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 22
- 230000007812 deficiency Effects 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 15
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract 4
- 244000269722 Thea sinensis Species 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 abstract description 21
- 208000024891 symptom Diseases 0.000 abstract description 16
- 206010012735 Diarrhoea Diseases 0.000 abstract description 14
- 206010030113 Oedema Diseases 0.000 abstract description 6
- 230000036528 appetite Effects 0.000 abstract description 6
- 235000019789 appetite Nutrition 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 244000096857 Dioscorea batatas Species 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000009835 boiling Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 11
- 235000013616 tea Nutrition 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 8
- 230000035488 systolic blood pressure Effects 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 235000021251 pulses Nutrition 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000025596 Cassia laevigata Species 0.000 description 2
- 235000006693 Cassia laevigata Nutrition 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940124513 senna glycoside Drugs 0.000 description 2
- 229940076742 senna leaves Drugs 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241001529821 Agastache Species 0.000 description 1
- 241000572565 Alpinia oxyphylla Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 240000008669 Hedera helix Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 101001002314 Mus musculus Gastrin Proteins 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 244000234609 Portulaca oleracea Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010042727 Swollen tongue Diseases 0.000 description 1
- 244000077233 Vaccinium uliginosum Species 0.000 description 1
- 235000011720 Vaccinium uliginosum Nutrition 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000006578 abscission Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- PYMYPHUHKUWMLA-VPENINKCSA-N aldehydo-D-xylose Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-VPENINKCSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000007215 black sesame Nutrition 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to a dampness eliminating traditional Chinese medicine composition which is mainly prepared from the following raw material medicines in parts by weight: 1-5 parts of coix seeds, 1-5 parts of phaseolus calcaratus, 1-6 parts of roasted malt, 1-8 parts of gordon euryale seeds, 3-8 parts of poria cocos and 1-8 parts of Chinese yam. The invention also provides application of the traditional Chinese medicine composition in preparing tea, food, health-care products or medicines for improving and treating spleen deficiency and excessive dampness metabolic syndrome. The spleen-tonifying dampness-eliminating composition provided by the invention is composed of natural plant raw materials, is scientific in proportioning, has a good dampness-eliminating effect, can obviously improve symptoms of spleen qi deficiency, weakness, poor appetite, edema, sticky lips, diarrhea and the like after being taken for a long time, and is simple in preparation process and taking mode.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine compositions, and in particular relates to dampness eliminating tea and application thereof.
Background
Metabolic Syndrome (MS) is a group of clinical syndromes characterized by a series of diseases or risk factors, and the treatment of metabolic syndrome with traditional Chinese medicines is very characteristic. From the perspective of the syndrome type of traditional Chinese medicine, in the MS type, the predominant type of dampness due to spleen deficiency is common, and it is seen that obesity is the main symptom and has symptoms such as fatigue. Among them, the gastrointestinal tract plays a central role in regulating immune homeostasis, which is considered to be the largest immune organ in the body, and spleen-qi deficiency is associated with the immune system and gastrointestinal function. The spleen and stomach function can not function normally, and the disorder of transportation and transformation of water dampness in vivo can cause the endogenous dampness. The damp-warm disease is characterized by the spleen and stomach as the center of pathological changes, the disease is in the qi system and is called "Zheng Juan", and if the disease is related to the liver and gallbladder, the location is not limited to the middle energizer, it is often called "Xian". The spleen-dampness and stomach-dampness pattern of Tianshi in the "Zhengjing" of damp-warm disease is designed to simplify and control the reproduction.
The pattern of spleen-qi deficiency is a common pattern in the clinical practice of traditional Chinese medicine, and is also a prerequisite for the occurrence of other spleen-deficiency patterns. Two kinds of results generally appear when damp pathogens inside and outside the human body are mutually hooked: the pathogenic dampness in the spleen and the damp-heat in the stomach are so called "the stomach is wet more in the body with exuberant yang, and the spleen is wet a little in the body with exuberant yin". The term "stomach-damp" and "spleen-damp" refer to damp-heat in the spleen and stomach with the pathogenic factors being predominant, the stomach-damp refers to damp-heat syndrome with predominant heat or predominant dampness, while the spleen-damp refers to damp-heat with the characteristic of heavy dampness and light dampness and can not completely mark the stomach or spleen. The spleen dampness and stomach dampness are the same disease, but the disease time is different. Damp-heat disease is characterized by the accumulation of qi in the spleen, which is mainly caused by the dampness-heat syndrome. At this time, great attention should be paid to the promotion of qi movement while resolving dampness, and the therapeutic principle of "dampness transforming when transforming is followed". When the disease progresses, dampness is accumulated and heat is transformed into heat, and when stomach heat is regarded as the serious condition, "stomach dampness". Therefore, damp-warm disease is usually manifested as early stage symptoms of "spleen dampness" followed by "stomach dampness". The damp-heat is the pathogenic factor of the yin-half and yang-half, and is a pair of opposite contradictory causes, so the clinical manifestations of the disease also have the contradictory phenomena that spleen dampness belongs to the heavy damp and light heat, the clinical manifestations are mostly seen in the symptoms of heat-intensity and light heat-intensity, early light and severe twitter, heavy and painful head and body, nausea and vomiting, dirty feeling, abdominal distension, stool pool, turbid urine, thirst without drinking, or thirst without taste, tastelessness and tastelessness, white and greasy tongue coating, white and slippery tongue coating, or white such as powder accumulation, and slightly red tongue texture, and the like.
Chinese patent document CN201910540333.6, published japanese 2019.08.09, discloses a spleen-invigorating and dampness-eliminating tea, comprising the following components: poria, semen Phaseoli, Coicis semen, semen Nelumbinis, rhizoma Dioscoreae, fructus Alpinae Oxyphyllae, thallus laminariae, herba Agastaches, herba Portulacae, radix Platycodi, semen lablab album, fructus Amomi, Glycyrrhrizae radix, and pericarpium Citri Tangerinae. Chinese patent document CN201910540333.6 discloses a herbal tea for invigorating spleen and eliminating dampness, which is prepared from the following important raw materials in parts by weight: 60 parts of gunny tea, 5 parts of honey, 7 parts of purslane, 8 parts of mushroom, 12 parts of peach, 10 parts of fig, 2 parts of black sesame oil, 5 parts of rhizoma atractylodis, 3 parts of mangnolia officinalis, 7 parts of dried orange peel, 5 parts of cortex acanthopanacis, 8 parts of phaseolus calcaratus and 7 parts of semen coicis.
The two traditional Chinese medicine compositions respectively comprise 14 medicines and 11 medicines, the number of medicines is large, the preparation procedure of the medicines is increased, and the preparation is complicated, so that the development of the traditional Chinese medicine composition capable of eliminating dampness and having a small number of medicines is necessary.
Disclosure of Invention
The first purpose of the invention is to provide a traditional Chinese medicine composition for eliminating dampness, aiming at the defects in the prior art.
The second purpose of the invention is to provide the application of the traditional Chinese medicine composition.
In order to achieve the purpose, the invention adopts the technical scheme that:
a traditional Chinese medicine composition for eliminating dampness is prepared from the following raw material medicines in parts by weight: 1-5 parts of coix seeds, 1-5 parts of phaseolus calcaratus, 1-6 parts of roasted malt, 1-8 parts of gordon euryale seeds, 3-8 parts of poria cocos and 1-8 parts of Chinese yam.
As a preferred example, the medicine is mainly prepared from the following raw material medicines in parts by weight: 2-4 parts of coix seeds, 2-4 parts of phaseolus calcaratus, 3-5 parts of roasted malt, 2-4 parts of gordon euryale seeds, 4-6 parts of poria cocos and 2-4 parts of Chinese yam.
More preferably, the medicine is mainly prepared from the following raw material medicines in parts by weight: 3 parts of coix seeds, 3 parts of phaseolus calcaratus, 4 parts of roasted malt, 3 parts of gordon euryale seeds, 5 parts of poria cocos and 3 parts of Chinese yam.
In order to achieve the purpose, the invention adopts the technical scheme that:
the application of the traditional Chinese medicine composition in preparing tea, food, health-care products or medicines for improving and treating spleen deficiency and excessive dampness metabolic syndrome.
The traditional Chinese medicines in the formula have the following effects:
coix seed: promoting metabolism of blood and water, promoting urination, eliminating edema, and relieving constipation, and reducing weight.
Small red beans: inducing diuresis to remove dampness, regulating blood and expelling pus, and relieving swelling and removing toxic substance. It is indicated for edema, beriberi, jaundice, dysentery, hematochezia, abscess, etc. Modern pharmacological discovery: the red bean contains more saponin which can stimulate the intestinal tract, so the red bean has good diuretic effect, can clear away toxin and redundant moisture in the body, promotes the metabolism of blood and moisture, and has the effects of promoting urination and eliminating water.
And (3) malt frying: move qi and promote digestion, invigorate spleen and stimulate appetite. It can be decocted or ground into powder for oral administration. For poor appetite due to spleen deficiency and fullness after eating, it is combined with Fu Ling and shan Yao to strengthen spleen and resolve dampness.
Gordon euryale seed: to strengthen kidney and check seminal emission, and to tonify spleen and check diarrhea. Has obvious effect of treating diarrhea caused by spleen deficiency and excessive dampness. In modern clinic, it is often combined with Dang Shen, Bai Zhu, shan Yao and Lian Zi to treat chronic diarrhea or dysentery due to spleen deficiency.
Tuckahoe, poria cocos: induce diuresis and drain dampness, invigorate spleen and calm heart. It is commonly indicated for edema, oliguria, dizziness and palpitation due to phlegm-fluid retention, spleen deficiency, poor appetite, loose stool, diarrhea, restlessness, palpitation, insomnia. Modern pharmacology shows that the poria cocos hormone has the effects of promoting urination, regulating immunity and the like.
Chinese yam: to invigorate the spleen, tonify the lung, strengthen the kidney and replenish vital essence. It is commonly used for diarrhea due to spleen deficiency and chronic dysentery; spleen deficiency, poor appetite, chronic diarrhea, leukorrhagia, frequent micturition, asthenic fever and diabetes. Modern pharmacology indicates that the crude yam polysaccharide can inhibit gastric emptying and small intestine propulsion of spleen deficiency mice, and meanwhile, spleen deficiency indexes and thymus indexes are increased to a certain extent, and it is preliminarily presumed that the regulation of immunity is one of action mechanisms of the crude yam polysaccharide.
The invention has the advantages that:
1. the composition and the proportion of the traditional Chinese medicine composition are obtained based on a large amount of clinical experience, and the treatment effect is more prominent.
2. The traditional Chinese medicine composition has the advantages of few types of raw material medicines, low price, easy preparation and low cost.
3. The traditional Chinese medicine composition is prepared from pure traditional Chinese medicines, has no toxic or side effect, can be taken after being brewed with boiling water, and is easily accepted by patients.
[ detailed description ] embodiments
The following provides a detailed description of specific embodiments of the present invention.
EXAMPLE 1 preparation of the Chinese medicinal composition of the present invention
3 parts of coix seed, 3 parts of phaseolus calcaratus, 4 parts of roasted malt, 3 parts of gordon euryale seed, 5 parts of poria cocos and 3 parts of Chinese yam, and the Chinese medicinal composition is prepared by brewing the Chinese medicinal raw materials with boiling water.
Example 2 preparation of the Chinese medicinal composition of the present invention
3 parts of coix seeds, 2 parts of phaseolus calcaratus, 5 parts of roasted malt, 1 part of gordon euryale seeds, 8 parts of poria cocos and 3 parts of Chinese yam are brewed by the Chinese medicinal raw materials and boiled water.
Example 3 preparation of the Chinese medicinal composition of the present invention
2 parts of coix seeds, 4 parts of red beans, 1 part of roasted malt, 8 parts of gordon euryale seeds, 5 parts of poria cocos and 2 parts of Chinese yam.
Example 4 preparation of the Chinese medicinal composition of the present Invention (IV)
4 parts of coix seed, 1 part of phaseolus calcaratus, 6 parts of roasted malt, 3 parts of gordon euryale seed, 4 parts of poria cocos and 4 parts of Chinese yam, and the Chinese medicinal composition is prepared by brewing the Chinese medicinal raw materials with boiling water.
Example 5 preparation of the Chinese medicinal composition of the present invention (V)
1 part of coix seed, 5 parts of phaseolus calcaratus, 4 parts of roasted malt, 2 parts of gordon euryale seed, 6 parts of poria cocos and 1 part of Chinese yam, and the Chinese medicinal composition is prepared by brewing the Chinese medicinal raw materials with boiling water.
Example 6 preparation of the Chinese medicinal composition of the present invention (VI)
5 parts of coix seed, 3 parts of phaseolus calcaratus, 3 parts of roasted malt, 4 parts of gordon euryale seed, 3 parts of poria cocos and 8 parts of Chinese yam, and the Chinese medicinal composition is prepared by brewing the Chinese medicinal raw materials with boiling water.
EXAMPLE 7 preparation of the Chinese medicinal composition of the present invention (VII)
3 parts of coix seed, 4 parts of phaseolus calcaratus, 1 part of roasted malt, 8 parts of gordon euryale seed, 5 parts of poria cocos and 2 parts of Chinese yam, and the Chinese medicinal composition is prepared by brewing the Chinese medicinal raw materials with boiling water.
EXAMPLE 8 preparation of the Chinese medicinal composition of the present invention (eight)
2 parts of coix seed, 1 part of phaseolus calcaratus, 6 parts of roasted malt, 3 parts of gordon euryale seed, 4 parts of poria cocos and 4 parts of Chinese yam, and the Chinese medicinal composition is prepared by brewing the Chinese medicinal raw materials with boiling water.
Example 9 preparation of the Chinese medicinal composition of the present invention (nine)
4 parts of coix seed, 5 parts of phaseolus calcaratus, 4 parts of roasted malt, 2 parts of gordon euryale seed, 6 parts of poria cocos and 1 part of Chinese yam, and the Chinese medicinal composition is prepared by brewing the Chinese medicinal raw materials with boiling water.
EXAMPLE 10 preparation of the Chinese medicinal composition of the present invention (Ten)
1 part of coix seed, 3 parts of phaseolus calcaratus, 3 parts of roasted malt, 4 parts of gordon euryale seed, 3 parts of poria cocos and 8 parts of Chinese yam, and the traditional Chinese medicine is prepared by brewing the traditional Chinese medicine raw materials with boiling water.
EXAMPLE 11 preparation of the Chinese medicinal composition of the present invention (eleven)
5 parts of coix seed, 2 parts of phaseolus calcaratus, 5 parts of roasted malt, 1 part of gordon euryale seed, 8 parts of poria cocos and 3 parts of Chinese yam, and the Chinese medicinal composition is prepared by brewing the Chinese medicinal raw materials with boiling water.
Example 12 clinical effects of the composition of the present invention on eliminating dampness
Xuan, male, 53 years old, poor appetite, sensation of sticky lips with halitosis, stool portion, pale tongue with white coating, tooth marks and thready pulse. 3g of coix seeds, 3g of phaseolus calcaratus, 3g of roasted malt, 3g of gordon euryale seeds, 5g of poria cocos and 3g of Chinese yam are used as small bags, and the small bags are respectively brewed with boiling water in the morning and at the evening every day. After one week of administration, the patient's symptoms were relieved.
Example 13 clinical effects of the composition of the present invention on eliminating dampness
Zhangyi, female, 28 years old, Pinsu is fat, sweet and thick in taste, slightly fat in body shape, slight edema of lower limbs, obvious hypodynamia, pale and swollen tongue with teeth marks, white and greasy coating and smooth pulse. A traditional Chinese medicine tea capable of tonifying spleen and eliminating dampness is prepared by taking 5 parts of coix seeds, 5 parts of phaseolus calcaratus, 6 parts of roasted malt, 8 parts of gordon euryale seeds, 8 parts of poria cocos and 8 parts of Chinese yam as small bags, and brewing the small bags with boiling water in the morning and at night every day. After continuous taking for 3 months, the symptoms of the patient are reduced, and the weight of the patient is reduced by 5 jin.
Example 14 clinical observations of the Chinese medicinal composition of the present invention in eliminating dampness
1 research data and methods
1.1 case data
All selected cases come from community health service centers of Putuo town in Putuo district of Shanghai city during 1 month to 6 months of 2020, 200 cases are observed in the current study by randomly selecting patients with spleen deficiency and excessive dampness metabolic syndrome differentiated by traditional Chinese medicine as the study objects according to the diagnosis sequence. At age 35-80 years, after patient consent and after consent from the hospital committee, they were distributed into two groups, control and intervention, in the form of random envelope grouping.
1.2 diagnostic criteria
(1) Western diagnostic criteria: the patients meet the diagnosis standard of metabolic syndrome established by the international diabetes alliance:
central obesity (waist of not less than 94cm for male, not less than 80cm for female, and BMI of not less than 25kg/m 2);
② the oil Triester (TG) rises above 1.7 mmol/L; high density lipoprotein cholesterol (HDL-C) reduces less than 1.0mmol/L in men and less than 1.3mmol/L in women; systolic Blood Pressure (SBP) is not less than 130mmHg or systolic blood pressure is not less than 85 mmHg; fasting Plasma Glucose (FPG) is greater than 5.6 mmol/L.
If any two of the first item and the second item are matched, the metabolic syndrome can be diagnosed.
(2) The diagnosis standard of traditional Chinese medicine is as follows: according to the literature of the Chinese medicine clinical diagnosis and treatment term of the Chinese medicine diagnostics 'clinical research guiding principle of new Chinese medicine' and the like, the patient is proved to be splenasthenic and exuberant. The patients have the main symptoms of obesity, drowsiness after eating, heaviness of the head, loose stool, abdominal distention, lassitude, hypodynamia, edema, vexation, dizziness, belch and the like in the secondary symptoms, and the tongue pulse is enlarged, tooth marks around the tongue, greasy fur, slippery pulse and soft pulse. If the patient has 2 subjects with the syndrome, or 1 subject with the syndrome + 2 secondary symptoms, it is determined as the syndrome of spleen deficiency with excessive dampness.
1.3 inclusion criteria
Age 35-80 years. ② the syndrome differentiation and classification of the traditional Chinese medicine is the patients with spleen deficiency and excessive dampness type metabolic syndrome. Thirdly, signing the informed consent. Fourthly, the writing and reading capability is ensured.
1.4 exclusion criteria
The drugs selected by the research scheme are allergic. ② accompanied with other physiological or pathological conditions which may affect the observation and judgment of effect indexes. Thirdly, the drug metabolism is affected by the serious damage of the center of gravity, the liver and the kidney. Fourthly, the characteristic population (pregnant women, psychosis, severe vaccinium uliginosum or late disease).
1.5 Exit Standard
First, no intervention measures are implemented as prescribed, and the therapeutic effect cannot be determined. ② the curative effect and safety can not be judged when the data is not complete. ③ serious adverse reaction, complication, special physiological change, and the like, and is difficult to continue the treatment. (poor response statistics for inclusion of adverse responders). And fourthly, judging whether the quitting/falling case is not included in the curative effect.
2 research methods
2.1 grouping method
The test method is characterized in that 100 cases of test subjects are divided into a control group and an intervention group by an envelope random grouping method, patients sign informed consent before experiments, and researchers collect basic information of the patients to ensure that the base lines of the two groups of study subjects are consistent.
2.2 methods of treatment
Control group: the control group is treated by conventional symptomatic treatment, and for hyperglycemia of patients, metformin hydrochloride sustained-release tablets (manufacturing enterprise: Shandong Si bang pharmaceutical Co., Ltd.; national Standard H20060230) are administered 1 tablet (0.5g) at a time, 1 time daily, and are taken after meal. For hypertension of patients, losartan potassium tablet (manufacturing enterprise: Zhejiang Huahai pharmaceutical industry Co., Ltd.; national drug standard H20070264) is administered 1 tablet (50mg) at a time, 1 time per day. Treatment was continued for 12 weeks. Any Chinese patent medicine and any Chinese medicinal preparation for reducing blood pressure are forbidden to take during observation period. Placebo (water) was taken at 200mL, warm in the morning and evening.
Intervention group: the dampness eliminating tea is taken twice a day on the basis of the treatment of a control group. (dampness eliminating tea, 15 parts of coix seed, 12 parts of phaseolus calcaratus, 15 parts of roasted malt, 30 parts of gordon euryale seed, 30 parts of tuckahoe and 30 parts of Chinese yam, 200mL of water is decocted, and the tea is taken warm in the morning and evening.)
Observation time: the two groups of treatment were observed continuously for 12 weeks, and if the patients had serious changes during the period and the medication was adjusted, the disease was considered to be dropped.
2.3 Observation index
The changes of Fasting Plasma Glucose (FPG), postprandial 2h blood glucose (2hPG), glycosylated hemoglobin (HbAlc) and the like before and after taking the medicine are observed and recorded.
Observing and recording four changes of blood fat of two groups of patients before and after taking the medicine, wherein the four changes comprise: total Cholesterol (TC), low density lipoprotein cholesterol (LDL-C), Triglyceride (TG), and high density lipoprotein cholesterol (HDL-C).
And observing the blood pressure changes of the two groups of patients before and after taking the medicine, including the change conditions of systolic pressure (SBP) and diastolic pressure (DBP).
Fourthly, adverse reaction: the occurrence of adverse reactions such as diarrhea, palpitation, allergy and the like during the treatment period of the two groups of patients is observed.
2.4 therapeutic efficacy criteria
The therapeutic effect judgment standard is as follows: according to the standard in the clinical research guiding principle of new traditional Chinese medicine, the obvious effect shows that the clinical symptoms of patients are obviously improved; effectively indicates that the clinical symptoms of the patient are all transferred; failure indicates no improvement or even an exacerbation of the clinical symptoms in the patient. The effective rate is (significant effect + effective)/the number of examples multiplied by 100%. 3 statistical methods
3.1 statistical analysis
By adopting SPSS16.0 statistical software, the clinical curative effect and the adverse reaction incidence rate are expressed in percent and are expressed in X 2 Verifying; the blood sugar, blood fat and blood pressure of the patient are expressed by t test; the difference is statistically significant when P < 0.05.
4 results of the study
There were no cases of abscission and withdrawal during the observation period, the total effective rate of treatment was compared, the intervention group was significantly higher than the control group, and the difference had statistical significance (P < 0.05), as shown in Table 1. Comparison of blood sugar conditions of patients with metabolic syndrome before treatment, PFG, 2hPG and HbAlc parameters of two groups of patients are compared, and no obvious difference exists (the P is more than 0.05); after treatment, PFG, 2hPG and HbAlc of the control group of the intervention group are all reduced, and the difference is statistically significant (the P is less than 0.05) when the intervention group is lower than the control group, which is shown in Table 2. Before the blood lipid condition of patients with metabolic syndrome is compared and treated, the TG, LDL-C, TC and HDL-C of an observation group and a control group have no statistical difference (the P is more than 0.05); after treatment, TG and LDL-C, TC decreased in both groups of patients, and the observed group was significantly lower than the control group with statistical differences (both P < 0.05); HDL-C in the observed group tended to increase, but the differences were not statistically significant (P > 0.05), as shown in Table 3. Before the blood pressure condition of metabolic syndrome patients is compared and treated, SBP and DBP of two groups of patients have no obvious difference; after treatment, both groups of patients had a decrease in both SBP and DBP, and the observed group was significantly lower than the control group, with statistical significance for the difference (mean P < 0.05). Therefore, the combined application of the ginseng and poria cocos spleen-tonifying and dampness-resolving decoction has a more obvious treatment effect on metabolic syndrome.
TABLE 1 comparison of the therapeutic efficacy of the two groups of patients (n,%)
| Group of | Number of examples | Show effect | Is effective | Invalidation | High efficiency | Comparison between groups |
| Control group | 100 | 81 | 11 | 8 | 92％ | χ 2 ＝3.911 |
| Intervention group | 100 | 80 | 17 | 3 | 97％ | P＝0.048＜0.05 |
Table 2 PFG, 2hPG and HbAlc improvement comparison before and after treatment (n ═ 100, x ± s)
TABLE 3 improvement ratio of TG, LDL-C, TC and HDL-C before and after treatment (n 100, x + -s)
Table 4 SBP versus DBP improvement before and after treatment (n 100,
)
example 15 animal experiments with the Chinese medicinal composition of the present invention
1 materials and methods
1.1 drugs and reagents
The preparation of the traditional Chinese medicine composition I comprises the following steps: the raw materials are weighed according to the parts by weight in the embodiment 1, decocted and concentrated until each milliliter contains 1g of the raw materials.
The preparation of the traditional Chinese medicine composition II comprises the following steps: the raw materials are weighed according to the parts by weight in the embodiment 2, decocted and concentrated until each milliliter contains 1g of the raw materials.
Preparing a first traditional Chinese medicine composition of a control group: weighing 3 parts of coix seeds, 3 parts of phaseolus calcaratus, 4 parts of roasted malt, 3 parts of gordon euryale seeds, 5 parts of poria cocos and 3 parts of bighead atractylodes rhizome according to the weight part ratio, and decocting and concentrating until each milliliter contains 1g of crude drugs.
Preparing a control group traditional Chinese medicine composition II: weighing 3 parts of coix seeds, 3 parts of phaseolus calcaratus, 4 parts of roasted malt, 3 parts of lotus seeds, 5 parts of rhizoma alismatis and 3 parts of poria cocos according to the weight part ratio, and decocting and concentrating until each milliliter contains 1g of crude drug.
Preparation of senna leaves: weighing 50g of boiling water of which the amount is 5 times that of the raw materials, decocting the raw materials for 3.5min with soft fire, filtering and concentrating the decoction to 1 g/mL.
The main reagents are as follows: d-xylose kit, mouse gastrin (Gas) ELISA kit.
1.2 animals
ICR mice 120, male, SPF grade, body mass (30 ± 2) g, provided by shanghai white probiotic technology ltd.
1.3 Main instruments
T2600 type uv-visible spectrophotometer (shanghai youke instruments & meters ltd.), desktop high speed centrifuge (germany HermLe), RE-52AA type rotary evaporator (shanghai subsp. biochemical instruments factory), ACS-6 type electronic price computing scale (Yongkang market prosperity electronic technology ltd.), DW-86L626 type medical low temperature storage box (Qingdao hai biomedical corporation), full automatic enzyme labeling instrument (hang zhou osheng instruments ltd.).
2 methods and results
2.1 animal Molding
ICR mice, the senna leaf group is filled with senna leaf with the dosage of 0.4g/d, the model is made for 5 weeks, and the blank group is filled with physiological saline with the same volume as the stomach every day.
2.2 protocol
96 mice which are successfully modeled are taken for the experiment. The model mice were randomly divided into five groups: 18 of the first inventive group, 19 of the second inventive group, 19 of the first control group, 20 of the second control group and 20 of the blank group were continuously administered for 6 weeks in the following manner:
the invention comprises the following components: 1.6ml/100g of decoction prepared by the traditional Chinese medicine composition I is used for intragastric administration every day.
The invention has the following group two: 1.6ml/100g of decoction prepared by the traditional Chinese medicine composition II is used for intragastric administration every day.
Control group one: the decoction prepared from the first Chinese medicinal composition of the control group is used for intragastric administration at a dose of 1.6ml/100g every day.
Control group two: and performing intragastric administration with 1.6ml/100g decoction prepared from the control group of Chinese medicinal composition II every day.
Blank group: the stomach was drenched with 1.6ml/100g deionized water every day.
After the model is successfully constructed, the mice are fasted for 24 hours without water prohibition, and then are gavaged with 0.2g/kg of D-xylose solution, and after 1 hour, the eyeballs are picked out, blood is taken, and the animals are killed. The colon of the mouse is picked up, frozen quickly by liquid nitrogen and stored in a refrigerator at the temperature of minus 80 ℃ for later use. Standing the blood for 1h, centrifuging at 4 deg.C and 3000r/min for 10min, separating the upper layer serum, and counting the red blood cells of mice by blood count plate counting method. Taking 10 mu L of the treated whole blood of the mouse, diluting the whole blood by 10000 times by using physiological saline, taking 1-2 drops of the whole blood to a red blood cell counting plate, recording the number of red blood cells by using a cell counter under a microscope, and measuring the serum level of the mouse by using an ELISA method.
2.2.1 evaluation of macroscopic indicators
Recording the food intake and the change of physical quality of each group of mice, and observing whether the mice have the symptoms of laziness, hunched back, bunching, squinting, withered and yellow hair color, rare hair color, white ear and tail color, and gray and lusterless abdominal surface hair, weakness in grabbing and struggling, absence of spirit when being frightened, soft stool, loose stool, diarrhea, increase of stimulated defecation rate and the like.
2.2.2 statistical methods
The results are expressed as mean ± SEM, with P < 0.05 being considered statistically different and P < 0.01 being considered very significantly statistically different by SPSS23.0 for t-test.
2.3 results
2.3.1 Effect of each Chinese medicinal composition on spleen deficiency of mice caused by senna leaves
The blank group of mice had normal activity, glossy back hair, sensitive response and normal feces. The mice in the model group have the spleen deficiency symptoms of loose stool, slow weight increase, bunching, no moving, perianal filthy, sparse fur, no luster and the like, and the model building of the spleen deficiency mice is successful. After 6 weeks of administration, the mice recovered to normal activities, the weight of the mice in the blank group was reduced, the weight of the mice in other groups was increased, the weight of the mice in the invention was closer to normal and better than that in the control group (P < 0.05), and the weight results are shown in Table 5. Therefore, the intervention of the traditional Chinese medicine on the mouse improves the spleen and stomach functions of the mouse, so that the normal excretion and the normal weight of the mouse are recovered.
TABLE 5 weight change (g) of mice in each group
Compared with the blank group, the serum D-xylose levels of the first group and the second group of the invention and the first control group, the second group and the blank group are obviously increased (P is less than 0.05), and the results are shown in Table 6. Therefore, the group of the invention can obviously improve the D-xylose level of spleen-deficiency animals, improve the digestion and absorption functions and has the function of strengthening the spleen.
TABLE 6 influence of Chinese medicinal composition on serum D-xylose of spleen deficiency mice
In conclusion, the symptoms before and after treatment by using the traditional Chinese medicine composition I, the traditional Chinese medicine composition II and the contrast traditional Chinese medicine are improved, the curative effect is obvious, the clinical curative effect of the traditional Chinese medicine composition I is equivalent to that of the contrast traditional Chinese medicine, and the clinical curative effect of the traditional Chinese medicine composition II is superior to that of the traditional Chinese medicine composition I and the contrast traditional Chinese medicine. The traditional Chinese medicine composition is simpler and more convenient to prepare, simple in use method, lower in cost and easier to popularize.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.
Claims (4)
1. The traditional Chinese medicine composition for eliminating dampness is characterized by being mainly prepared from the following raw material medicines in parts by weight: 1-5 parts of coix seed, 1-5 parts of phaseolus calcaratus, 1-6 parts of roasted malt, 1-8 parts of gordon euryale seed, 3-8 parts of poria cocos and 1-8 parts of Chinese yam.
2. The traditional Chinese medicine composition according to claim 1, which is mainly prepared from the following raw material medicines in parts by weight: 2-4 parts of coix seeds, 2-4 parts of phaseolus calcaratus, 3-5 parts of roasted malt, 2-4 parts of gordon euryale seeds, 4-6 parts of poria cocos and 2-4 parts of Chinese yam.
3. The traditional Chinese medicine composition according to claim 1, which is mainly prepared from the following raw material medicines in parts by weight: 3 parts of coix seeds, 3 parts of phaseolus calcaratus, 4 parts of roasted malt, 3 parts of gordon euryale seeds, 5 parts of poria cocos and 3 parts of Chinese yam.
4. Use of the Chinese medicinal composition of any one of claims 1 to 3 in the preparation of tea, food, health-care product or medicament for improving and treating spleen deficiency and excessive dampness metabolic syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210907559.7A CN115040616A (en) | 2022-07-29 | 2022-07-29 | Dampness eliminating tea and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210907559.7A CN115040616A (en) | 2022-07-29 | 2022-07-29 | Dampness eliminating tea and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115040616A true CN115040616A (en) | 2022-09-13 |
Family
ID=83168107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210907559.7A Pending CN115040616A (en) | 2022-07-29 | 2022-07-29 | Dampness eliminating tea and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115040616A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111955578A (en) * | 2020-09-10 | 2020-11-20 | 贵州食品工程职业学院 | Coix seed compound granular tea and preparation method thereof |
| CN111972524A (en) * | 2019-05-22 | 2020-11-24 | 四川兰冰康源食品有限公司 | Coix seed substituted tea and preparation method thereof |
-
2022
- 2022-07-29 CN CN202210907559.7A patent/CN115040616A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111972524A (en) * | 2019-05-22 | 2020-11-24 | 四川兰冰康源食品有限公司 | Coix seed substituted tea and preparation method thereof |
| CN111955578A (en) * | 2020-09-10 | 2020-11-20 | 贵州食品工程职业学院 | Coix seed compound granular tea and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 唐仕勇: "参苓白术散治疗小儿泄泻的机理与体会", 现代中医药, no. 06, pages 38 - 39 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028900B (en) | Traditional Chinese medicine for treating metabolic syndrome and preparation method thereof | |
| WO2012034498A1 (en) | Product of functional health food that enhances organ immunity | |
| AU1966399A (en) | Compositions for weight reduction | |
| WO2022011880A1 (en) | Spleen strengthening traditional chinese medicine composition and application thereof | |
| CN115364170B (en) | Sugar metabolism regulator and preparation method and application thereof | |
| CN108434242A (en) | A kind of pharmaceutical composition, preparation method and its usage for treating diabetes and its complication | |
| CN101002929A (en) | Medicine for treating functional hypopepsia or complicating Helicobacter pylori infection, and its preparing method | |
| CN107568375A (en) | A kind of adlay slim tea and preparation method thereof | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN114306424B (en) | Traditional Chinese medicine composition for treating obesity and preparation method and application thereof | |
| CN114224998B (en) | Traditional Chinese medicine composition, preparation and application for treating spleen-kidney yang deficiency type functional dyspepsia | |
| CN115040616A (en) | Dampness eliminating tea and application thereof | |
| CN108853427A (en) | A kind of Chinese medicinal formulae for treating overweight/obesity type Stein-Leventhal syndrome | |
| CN101579496B (en) | Application of Chinese medicine composition in preparation of medicine for treating atypical hyperplasia of gastric mucosa | |
| CN112336802B (en) | Traditional Chinese medicine composition for improving glycolipidosis metabolism of diabetes and application thereof | |
| CN116350741B (en) | Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof | |
| CN104225115B (en) | A kind of medicine for treating fatty liver and its application | |
| CN103656196A (en) | Traditional Chinese medicine composition for treating cutaneous pruritus caused by diabetes and preparation method thereof | |
| CN116059302B (en) | Traditional Chinese medicine composition for treating gastrointestinal motility diseases and preparation method and application thereof | |
| CN116763880B (en) | Traditional Chinese medicine composition and preparation for treating functional dyspepsia accompanied with emaciation and application of traditional Chinese medicine composition and preparation | |
| CN116440224B (en) | Traditional Chinese medicine composition, preparation and preparation method | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof | |
| AU2021102527A4 (en) | A tonifying and balancing restorative paste | |
| CN102600436A (en) | Traditional Chinese medicine compound preparation for treating gastric cancer and preparation method thereof | |
| CN101057901B (en) | Traditional Chinese medicinal composition for curing hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220913 |
|
| RJ01 | Rejection of invention patent application after publication |